TransMedics (TMDX) Depreciation & Amortization (CF) (2018 - 2026)

TransMedics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 93.32% year-over-year to $11.9 million in Q1 2026; TTM through Mar 2026 was $32.8 million, a 53.3% increase from a year earlier, with the FY2025 full-year figure at $27.2 million, up 37.59% from the prior year.
• Depreciation & Amortization (CF) climbed to $11.9 million in Q1 2026 per TMDX's latest filing, from $7.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $11.9 million in Q1 2026 and bottomed at $507000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $4.3 million (2024), against an average of $4.1 million.
• Across the five-year window, Depreciation & Amortization (CF) climbed 13.93% in 2022 and jumped 234.27% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.3 million in 2022, then jumped by 180.54% to $3.6 million in 2023, then soared by 57.56% to $5.7 million in 2024, then soared by 31.48% to $7.5 million in 2025, then surged by 58.86% to $11.9 million in 2026.
• Per Business Quant, the three latest TMDX Depreciation & Amortization (CF) figures stand at $11.9 million (Q1 2026), $7.5 million (Q4 2025), and $6.8 million (Q3 2025).